Table 3. . Treatment of toxicity in the patient population.
ICIs | Patients with steroids (n) | Patients with hormone (n) | Patients with biologic therapy (n) |
---|---|---|---|
Atezolizumab | 2 | - | - |
Avelumab | 1 | ||
Durvalumab | - | 1 | |
Ipilimumab | 10 | 9 | |
Nivolumab | 21 | 17 | 2 |
Pembrolizumab | 12 | 7 | 3 |
Combination | 4 | 4 | 1 |
Total (%) | Steroids 53% | Hormone 40% | Biologic 7% |
ICI: Immune checkpoint inhibitor.